3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
131
Squamous Cell Carcinoma of Head and Neck
75
Lung Neoplasms
47
Head and Neck Neoplasms
45
Urinary Bladder Neoplasms
43
Parkinson Disease 4, Autosomal Dominant Lewy Body
33
Oropharyngeal Neoplasms
32
Nasopharyngeal Carcinoma
31
Biliary Tract Neoplasms
31
Uterine Cervical Neoplasms
29
Cholangiocarcinoma
28
Esophageal Squamous Cell Carcinoma
24
Neoplasms
23
Carcinoma
23
Neoplasm Metastasis
22
Small Cell Lung Carcinoma
21
Ovarian Neoplasms
21
Carcinoma, Squamous Cell
20
Stomach Neoplasms
18
Colorectal Neoplasms
18
Carcinoma, Transitional Cell
17
Pancreatic Neoplasms
16
Esophageal Neoplasms
16
Mesothelioma, Malignant
15
Gallbladder Neoplasms
15
Mouth Neoplasms
14
Laryngeal Neoplasms
13
Hypopharyngeal Neoplasms
12
Endometrial Neoplasms
11
Triple Negative Breast Neoplasms
10
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
Cisplatin
×
1 year
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA